Management – Paul G Higham

Immatics, a leading cancer immunotherapy company, is beginning the next phase of its growth developing a number of important new technologies, having recently announced the major agreement with the University of Texas MD Anderson Cancer Center and the launch of...

Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies

Immatics US, Inc. has secured over $60m in total funding – more than $40m from the parent company Immatics Biotechnologies GmbH and a $19.7 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) MD Anderson Cancer Center is a shareholder in...